Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, with no statistically significant difference observed between the treatment ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my VTGN stock update and a look ahead.

The only FDA-approved option is Spravato, a nasal spray made from a derivative of ketamine, which is used for treatment-resistant depression and major depressive disorder in adults. Ketamine is ...